|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 国际疼痛研究协会疼痛定义修订版:概念、挑战和折中显示文摘现行国际疼痛研究协会(IASP)将疼痛定义为'与实际或潜在组织损伤,或描述的类似损伤相关的一种不愉快的感觉和情感体验',该定义是由一个分类小组委员会推荐,并于1979年被IASP理事会所采纳。这一定义已被疼痛领域的卫生保健专业人士和研究人员广泛接受,并被一些行业、政府及非政府组织(包括世界卫生组织)所采用。近年来,一些业内人士认为,随着对疼痛更深入的了解,有必要对这个定义重新审定,并提出了修改建议。因此,2018年,IASP成立了一个主席特别工作小组,该小组是由14名来自多个国家的在疼痛相关的临床和基础科学方面拥有广泛专业知识的人员组成,其任务是评估现行定义及其附带注释,并对其保留还是修改提出建议。本文提供了关键概念的摘要、对IASP会员和公众评论的分析以及两年内委员会对疼痛定义和注释的最终修订意见。特别工作小组最后建议将疼痛定义修改为'与组织损伤或潜在组织损伤相关或类似相关的一种不愉快的感觉和情感体验',并将原来的附带注释更新为一系列简要说明并提供相关词源。今年年初,IASP理事会一致接受了修订后的定义和注释。 | Raja SN.Carr DB Cohen M.Finnerup NB Flor H.Gibson S Keefe FJ.Mogil JS Ringkamp M.Sluka KA Song XJ.Stevens B Sullivan MD.Tutelman PR Ushida T.Vader K 程志祥(译) 许继军(译) 程建国(审校) 刘先国(审校) 刘延青(审校) | 2020 | 中华疼痛学杂志2020，16，5： | 137 |
| 2 | 慢性神经病理性疼痛显示文摘国际疼痛学会(IASP)设立特别工作组与世界卫生组织(WHO)的代表密切合作,制定了更具系统性的慢性疼痛分类,并收录于ICD-11编码。本文从疼痛分类的角度,将超过3个月的持续性或反复性疼痛有关的神经系统疾病或损伤进行了重新分类。新分类列出了慢性周围神经病理性疼痛中最常见的疾患:三叉神经痛、周围神经损伤、痛性多发神经病变、带状疱疹后神经痛和痛性神经根病变。同时也列出了慢性中枢神经病理性疼痛中最常见的疾患:脊髓或脑损伤后疼痛、卒中后疼痛、多发性硬化相关性疼痛。该分类中未明确提及的疾病类型将在ICD-11的其他分类中列出。慢性神经病理性疼痛在临床中的发病率高,受到医务工作者高度重视,但ICD-10对其定义或不充分,或有所缺失。IASP特别工作组提供了简要的疾病类型定义,以用于临床诊断,并向WHO提交了这些定义的详细内容。世界上约10%的人群经历过神经病理性疼痛,而现有的治疗方式却无法有效缓解其中大部分人的疼痛。在ICD-11中,专家们将慢性神经病理性疼痛进行了精细分类,这对于应对相关疼痛治疗中的挑战和满足公共健康需求十分必要。 | 杜涛(编译) 袁文茜(编译) 曹伯旭(编译) 胡永生(编译) 卢光(编译) 李俊驰(编译) 赵序利(编译) 宋学军(审校) 刘小立(审校) 万有(审校) 樊碧发(审校) 韩济生(审校) Scholz J Finnerup NB Attal N | 2021 | 中国疼痛医学杂志2021，27，7： | 21 |
| 3 | Transient Free Convection and Thermal Stratification in Uniformly-Heated Partially-Filled Horizontal Cylindrical and Spherical Vessels显示文摘Anintegral approach has been used to analyze the development of the free convection boundary layer on heated concave surfaces,such as those in horizontal cylinders or a sphere,Based on the non-dimensional laminar and turbulent velocity and temperature profiles closed form expressions for the boundary layer thickness,velocity scale as well as the boundary layer commencement after the point of instability are obtained.In addition,the mass flowrate to the thermal stratified rgeion is given. | C.M.Yu Professor,Department of Thermal Engineering,University of Science and Technology Beijing,Beijing 100083,ChinaN.U.Aydemir Atomic Energy of Canada Limited,Whiteshell Nuclear Research Establishment,Pinawa,Manitoba,ROE 1LO,CanadaJ.E.S.Venart Fire Science Centre,University of New Brunswick,P.O.Box 4400,Fredericton,NB E3B 5A3,Canada | 1992 | Journal of Thermal Science1992，1，2： | 13 |
| 4 | Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease显示文摘The prevalence of obesity and related conditions like non-alcoholic fatty liver disease(NAFLD) is increasing worldwide and therapeutic options are limited.Alternative treatment options are therefore intensively sought after.An interesting candidate is the natural polyphenol resveratrol(RSV) that activates adenosinmonophosphate-activated protein kinase(AMPK) and silent information regulation-2 homolog 1(SIRT1).In addition,RSV has known anti-oxidant and anti-inflammatory effects.Here,we review the current evidence for RSVmediated effects on NAFLD and address the different aspects of NAFLD and non-alcoholic steatohepatitis(NASH) pathogenesis with respect to free fatty acid(FFA) flux from adipose tissue,hepatic de novo lipogenesis,inadequate FFA β-oxidation and additional intra- and extrahepatic inflammatory and oxidant hits.We review the in vivo evidence from animal studies and clinical trials.The abundance of animal studies reports a decrease in hepatic triglyceride accumulation,liver weight and a general improvement in histological fatty liver changes,along with a reduction in circulating insulin,glucose and lipid levels.Some studies document AMPK or SIRT1 activation,and modulation of relevant markers of hepatic lipogenesis,inflammation and oxidation status.However,AMPK/SIRT1-independent actions are also likely.Clinical trials are scarce and have primarily been performed with a focus on overweight/obese participants without a focus on NAFLD/NASH and histological liver changes.Future clinical studies with appropriate design are needed to clarify the true impact of RSV treatment in NAFLD/NASH patients. | Sara Heebll Karen Louise Thomsen Steen B Pedersen Hendrik Vilstrup Jacob George Henning Grnbk | 2014 | World Journal of Hepatology2014，6，4： | 11 |
| 5 | Bariatric surgery in patients with non-alcoholic fatty liver disease-from pathophysiology to clinical effects显示文摘Non-alcoholic fatty liver disease(NAFLD) is increasingly recognized as a significant liver disease,and it covers the disease spectrum from simple steatosis with a risk of development of non-alcoholic steatohepatitis(NASH) to fibrosis,subsequent cirrhosis,end-stage liver failure,and liver cancer with a potential need for liver transplantation.NAFLD and NASH are closely related to obesity,metabolic syndrome,and type 2 diabetes(T2 D).The role of gut hormones,especially glucagon-like peptide 1(GLP-1),is important in NAFLD.Bariatric surgery has the potential for inducing great weight loss and may improve the symptoms of metabolic syndrome and T2 D.Recent data demonstrated significant effects of bariatric surgery on GLP-1 and other gut hormones and important lipid metabolic and inflammatory abnormalities in the pathophysiology of NAFLD.Therefore,bariatric surgery may reverse the pathological liver changes in NAFLD and NASH patients.In the present review,we describe NAFLD and NASH pathophysiology and the primary effects of bariatric surgery on metabolic pathways.We performed a systematic review of the beneficial and harmful effects and focused on changes in liver disease severity in NAFLD and NASH patients.The specific focus was liver histopathology as assessed by the invasive liver biopsy.Additionally,we reviewed several non-invasive methods used for the assessment of liver disease severity following bariatric surgery. | Tea L Laursen Christoffer A Hagemann Chunshan Wei Konstantin Kazankov Karen L Thomsen Filip K Knop Henning Grønbæk | 2019 | World Journal of Hepatology2019，11，2： | 11 |
| 6 | 长期应用埃索美拉唑是维持已愈合糜烂性食管炎疗效及控制胃食管反流症状的有效方法显示文摘 | Johnson DA Benjamin SB Vakil NB Goldstein JL Lamet M Whipple J Damico D Hamelin B 钟捷 | 2002 | 中华消化杂志2002，22，12： | 6 |
| 7 | Trefoil factors in inflammatory bowel disease显示文摘Inflammatory bowel disease(IBD),which comprises ulcerative colitis and Crohn’s disease,is characterized by inflammation of the gastrointestinal tract.The trefoil factors 1,2,and 3(TFF1-3)are a family of peptides that play important roles in the protection and repair of epithelial surfaces,including the gastrointestinal tract.TFFs may be involved in IBD pathogenesis and are a potential treatment option.In the present review,we describe the TFF family and their potential role in IBD by summarizing the current knowledge of their expression,possible function and pharmacological role in IBD. | Luise Aamann Else Marie Vestergaard Henning Grφnbk | 2014 | World Journal of Gastroenterology2014，20，12： | 6 |
| 8 | New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report显示文摘BACKGROUND Progressive familial intrahepatic cholestasis(PFIC)encompasses a group of autosomal recessive disorders with high morbidity and mortality.Variants in the gene encoding tight junction protein-2(TJP2)have been linked to PFIC type 4(PFIC4),which predominantly presents in childhood.However,there are only limited data from adults with TJP2-related PFIC4.We report a family with an autosomal recessive disorder with a novel variant in the TJP2 gene in adults with very variable expression of PFIC4.CASE SUMMARY The index patient presented at 19 years old with liver cirrhosis and variceal bleeding and was treated with endoscopic banding and beta-blockers.In 2018,he developed primary liver cancer that was treated with radiofrequency ablation followed by liver transplantation in 2019.Genetic testing revealed a novel homozygous TJP2 variant causing PFIC4(TJP2([NM_004817.3]:c.[3334C>T];[3334C>T])).The consanguineous family consists of the father and mother(both heterozygous)and their 12 children,of which five carry the variant in a homozygous state;however,these five siblings have highly variable expression of PFIC4.Two homozygous brothers had cirrhosis and portal hypertension at diagnosis at the ages of 19 and 36.Two other homozygous brothers,age 23 and 19,and the homozygous sister,age 21,have elevated liver enzymes but presently no cirrhosis,which may suggest an age-dependent penetrance.In addition,five sisters had severe and mild intrahepatic cholestasis of pregnancy and carry the TJP2 variant in a homozygous and heterozygous state,respectively.CONCLUSION This novel TJP2 variant is associated with PFIC4 causing severe liver disease with cirrhosis and primary liver cancer in adolescents/adults. | Chun-Shan Wei Naja Becher Jenny Blechingberg Friis Peter Ott Ida Vogel Henning Grønbæk | 2020 | World Journal of Gastroenterology2020，26，5： | 6 |
| 9 | Metabolic and hepatic effects of liraglutide,obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis显示文摘AIM To evaluate the pharmacodynamics of compounds in clinical development for nonalcoholic steatohepatitis(NASH) in obese mouse models of biopsy-confirmedNASH.METHODS Male wild-type C57 BL/6 J mice(DIO-NASH) and Lep^(ob/ob)(ob/ob-NASH) mice were fed a diet high in trans-fat(40%), fructose(20%) and cholesterol(2%) for 30 and 21 wk, respectively. Prior to treatment, all mice underwent liver biopsy for confirmation and stratification of liver steatosis and fibrosis, using the nonalcoholic fatty liver disease activity score(NAS) and fibrosis staging system. The mice were kept on the diet and received vehicle, liraglutide(0.2 mg/kg, SC, BID), obeticholic acid(OCA, 30 mg/kg PO, QD), or elafibranor(30 mg/kg PO, QD) for eight weeks. Within-subject comparisons were performed on changes in steatosis, inflammation, ballooning degeneration, and fibrosis scores. In addition, compound effects were evaluated by quantitative liver histology, including percent fractional area of liver fat, galectin-3, and collagen 1 a1.RESULTS Liraglutide and elafibranor, but not OCA, reduced body weight in both models. Liraglutide improved steatosis scores in DIO-NASH mice only. Elafibranor and OCA reduced histopathological scores of hepatic steatosis and inflammation in both models, but only elafibranor reduced fibrosis severity. Liraglutide and OCA reduced total liver fat, collagen 1 a1, and galectin-3 content, driven by significant reductions in liver weight. The individual drug effects on NASH histological endpoints were supported by global gene expression(RNA sequencing) and liver lipid biochemistry.CONCLUSION DIO-NASH and ob/ob-NASH mouse models show distinct treatment effects of liraglutide, OCA, and elafibranor, being in general agreement with corresponding findings in clinical trials for NASH. The present data therefore further supports the clinical translatability and utility of DIO-NASH and ob/ob-NASH mouse models of NASH for probing the therapeutic efficacy of compounds in preclinical drug development for NASH. | Kirstine S Tolbol Maria NB Kristiansen Henrik H Hansen Sanne S Veidal Kristoffer TG Rigbolt Matthew P Gillum Jacob Jelsing Niels Vrang Michael Feigh | 2018 | World Journal of Gastroenterology2018，24，2： | 5 |
| 10 | Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt显示文摘AIM:To evaluate long-term complications and survival in patients with Budd-Chiari syndrome (BCS) referred to a Danish transjugular intrahepatic portosystemic shunt (TIPS) centre.METHODS:Twenty-one consecutive patients from 1997-2008 were retrospectively included [15 women and 6 men,median age 40 years (range 17-66 years)].Eighteen Danish patients came from the 1.8 million catchment population of Aarhus University Hospital and three patients were referred from Scandinavian hospitals.Management consisted of tests for underlying haematological,endocrinological,or hypercoagulative disorders parallel to initiation of specific treatment of BCS.RESULTS:BCS was mainly caused by thrombophilic (33%) or myeloproliferative (19%) disorders.Fortythree percents had symptoms for less than one week with ascites as the most prevalent finding.Fourteen (67%) were treated with TIPS and 7 (33%) were manageable with treatment of the underlying condition and diuretics.The median follow-up time for the TIPS-treated patients was 50 mo (range 15-117 mo),and none required subsequent liver transplantation.Ascites control was achieved in all TIPS patients with a marked reduction in the dose of diuretics.A total of 14 TIPS revisions were needed,mostly of uncovered stents.Two died during follow-up:One non-TIPS patient worsened after 6 mo and died in relation to transplantation,and one TIPS patient died 4 years after the TIPS-procedure,unrelated to BCS.CONCLUSION:In our BCS cohort TIPS-treated patients have near-complete survival,reduced need for diuretics and compared to historical data a reduced need for liver transplantation. | Anders Bay Neumann Stine Degn Andersen Dennis Tφnner Nielsen Peter Holland-Fischer Hendrik Vilstrup Henning Grφnbk | 2013 | World Journal of Hepatology2013，5，1： | 5 |
| 11 | Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study显示文摘 | Lisbet Gr?nb?k Hendrik Vilstrup Peter Jepsen | 2013 | Journal of Hepatology2013，，： | 3 |
| 12 | Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis显示文摘AIM:To investigate the effect of transjugular intra-hepatic porto-systemic shunt (TIPS) on malnutrition in portal hypertensive cirrhotic patients.METHODS: Twenty-one patients with liver cirrhosis and clinical indications for TIPS insertion were investigated before and 1, 4, 12, 52 wk after TIPS. For each patient we assayed body composition parameters [dry lean mass, fat mass, total body water (TBW)], routine liver and kidney function tests, and free fatty acids (FFA). Glucose and insulin were measured for the calculation of the homeostasis model assessment insulin resistance (HOMA-IR); liver function was measured by the galactose elimination capacity (GEC); the severity of liver disease was graded by model for end-stage liver disease (MELD).RESULTS: Porto-systemic gradient decreased after TIPS (6.0±2.1 mmHg vs 15.8±4.8 mmHg, P<0.001). Patients were divided in two groups according to initial body mass index. After TIPS, normal weight patients had an increase in dry lean mass (from 10.9±5.9 kg to 12.7±5.6 kg, P=0.031) and TBW (from 34.5±7.6 L to 40.2±10.8 L,P=0.007), as well as insulin (from 88.9±49.2 pmol/L to 164.7±107.0 pmol/L,P=0.009) and HOMA-IR (from 3.36%±2.18% to 6.18%±4.82%,P=0.023). In overweight patients only FFA increased significantly (from 0.59±0.24 mmol/L to 0.93±0.34 mmol/L, P=0.023).CONCLUSION: TIPS procedure is effective in lowering portal pressure in patients with portal hypertension and improves body composition without significant changes in metabolic parameters. | Jonathan Montomoli Peter Holland-Fischer Giampaolo Bianchi Henning GrФnbk Hendrik Vilstrup Giulio Marchesini Marco Zoli | 2010 | World Journal of Gastroenterology2010，16，3： | 3 |
| 13 | 《斯大林和毛泽东的对话》显示文摘 | NB科瓦廖夫 | 1992 | 国外社科信息1992，，21： | 2 |
| 14 | Blue nevus of the uterine cervix 显示文摘 | Goldman RL Fredmen NB | 1967 | Cancer1967，20，： | 2 |
| 15 | No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion显示文摘 | Christian Mortensen Stine Karlsen Henning Gr?nb?k Dennis T. Nielsen Susanne Frevert Jens O. Clemmesen S?ren M?ller J?rgen S. Jensen Flemming Bendtsen | 2013 | Liver Int2013，，9： | 2 |
| 16 | Identification of the β-subunit for nongastric H-K-ATPase in rat anterior prostate显示文摘 | Pestov NB Korneenko TV Radkov R | 2004 | Am J Physiol Cell Physiol2004，286，6： | 1 |
| 17 | Inhibition of release of taurine and excitatory amino acids in ischemia and neuroprotection显示文摘 | Kimelberg HK Nestor NB Feustel PJ | 2004 | Neurochem Res2004，29，1： | 1 |
| 18 | Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management 显示文摘 | Massie BM Shah NB | 1997 | American Heart Journal1997，133，6： | 1 |
| 19 | Alcohol moduhes alveolar macrophage tumor necrosis factor-alpha superoxide anion,and nitric oxide secrition in the rat显示文摘 | Dsouza NB | 1996 | Alcohol Clin Express1996，20，1： | 1 |
| 20 | Variations in tight junctions and gap junctions in mammalian tissues显示文摘 | Gilula NB | 1972 | J Cell Biol1972，53，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员